logo
logo
Treace Medical Concepts, Inc.

Treace Medical Concepts, Inc.

NASDAQ•TMCI
CEO: Mr. John T. Treace
セクター: Healthcare
業種: Medical - Devices
上場日: 2021-04-23
Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity. It also provides Lapiplasty mini-incision system designed to allow the Lapiplasty procedure to be performed through a 3.5cm incision. In addition, the company offers Adductoplasty system designed for reproducible realignment, stabilization, and fusion of the midfoot. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.
連絡先情報
100 Palmetto Park Place, Ponte Vedra, FL, 32081, United States
904-373-5940
www.treace.com
時価総額
$133.17M
PER (TTM)
-2.6
31.5
配当利回り
--
52週高値
$10.40
52週安値
$2.02
52週レンジ
1%
順位58Top 85.6%
2.3
F-Score
改良版 Piotroski 分析
6年ファンダメンタル
弱い • 2.3 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2020-2025

財務ダッシュボード

Q3 2025 データ

売上高

$50.21M+11.37%
直近4四半期の推移

EPS

-$0.26+4.00%
直近4四半期の推移

フリーCF

-$11.90M-19.07%
直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

Q3 Revenue Growth Strong Q3 Revenue reached $50.2M, showing 11.4% growth driven by increased kit sales volume compared to prior year.
Nine-Month Net Loss Narrows Nine-month Net Loss improved by $5.6M to $49.6M, reflecting better operating results compared to the 2024 period.
Operating Expenses Controlled Total operating expenses for nine months decreased $0.7M, down 0.4% to $167.6M, despite increased G&A costs.
Initial Distributor Sales Recorded Q3 2025 revenue included $6.0M from initial stocking distributor orders, a new revenue stream absent in 2024.

リスク要因

Competition Pressures Lapiplasty Increased competition and evolving surgeon preferences negatively impact flagship Lapiplasty System sales, potentially reducing revenue growth.
Macroeconomic Demand Uncertainty Inflation, recession fears, and insurance deductibles may negatively impact consumer demand for elective surgery products.
Pending Litigation Exposure Pending federal securities class action and patent infringement suits against Stryker and ZB create material uncertainty.
Gross Margin Pressure Q3 COGS increased 17.4% due to higher direct costs and inventory provisions, partially offsetting gross profit gains.

見通し

Liquidity Forecast Sufficient Current cash ($7.7M) and securities ($49.7M) expected to fund operations for at least twelve months from issuance date.
Debt Extension Intention Intends to extend the interest-only period on MidCap term loan to 60 months based on meeting revenue levels.
Continued Innovation Investment Focus remains on R&D for next-generation innovations, including Nanoplasty and Percuplasty system expansion plans.
Near-Term Loss Expected Expect to operate at a loss in the near term, financed by existing cash, marketable securities, and expected revenues.

同業比較

売上高 (TTM)

Enhabit, Inc.EHAB
$1.05B
+1.0%
Bioventus Inc.BVS
$563.83M
+1.6%
The Oncology Institute, Inc.TOI
$461.04M
+21.7%

粗利益率 (最新四半期)

Semler Scientific, Inc.SMLR
91.5%
+0.1pp
Delcath Systems, Inc.DCTH
87.2%
+1.9pp
RxSight, Inc.RXST
79.9%
+24.3pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
SRDX$614.51M-34.8-15.6%19.2%
DSGN$582.74M-8.6-30.6%0.8%
EHAB$567.23M-47.7-2.2%42.0%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
-9.9%
成長鈍化
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
25%
キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年2月26日
|
EPS:-$0.15
|
売上高:$61.87M
財務レポート
財務データ
全年度

  • Form 10-Q - Q3 2025

    会計期末: 2025年9月30日|提出日: 2025年11月6日|
    売上高: $50.21M+11.4%
    |
    EPS: $-0.26+4.0%
    予想を上回る

  • Form 10-Q - Q2 2025

    会計期末: 2025年6月30日|提出日: 2025年8月7日|
    売上高: $47.39M+6.6%
    |
    EPS: $-0.28-17.6%
    予想を上回る

  • Form 10-Q - Q1 2025

    会計期末: 2025年3月31日|提出日: 2025年5月8日|
    売上高: $52.57M+2.9%
    |
    EPS: $-0.25-16.7%
    予想を上回る

  • Form 10-K - FY 2024

    会計期末: 2024年12月31日|提出日: 2025年2月27日|
    売上高: $209.36M+11.9%
    |
    EPS: $-0.90-11.1%
    予想を下回る

  • Form 10-Q - Q3 2024

    会計期末: 2024年9月30日|提出日: 2024年11月5日|
    売上高: $45.09M+10.6%
    |
    EPS: $-0.25-10.7%
    予想を上回る

  • Form 10-Q - Q2 2024

    会計期末: 2024年6月30日|提出日: 2024年8月6日|
    売上高: $44.46M+6.0%
    |
    EPS: $-0.34+70.0%
    予想を下回る

  • Form 10-Q - Q1 2024

    会計期末: 2024年3月31日|提出日: 2024年5月7日|
    売上高: $51.11M+21.1%
    |
    EPS: $-0.30+36.4%
    予想を上回る

  • Form 10-K - FY 2023

    会計期末: 2023年12月31日|提出日: 2024年2月27日|
    売上高: $187.12M+31.9%
    |
    EPS: $-0.81-5.2%
    予想を下回る